<DOC>
	<DOCNO>NCT02508467</DOCNO>
	<brief_summary>This Phase 1 , open-label , first-in-human ( FIH ) study design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , preliminary antineoplastic activity BLU- 554 administer orally patient hepatocellular carcinoma ( HCC ) . The study consist 2 part , dose-escalation part ( Part 1 ) expansion part ( Part 2 ) explore daily ( qd ) twice daily ( bid ) dosing schedule .</brief_summary>
	<brief_title>A Phase 1 Study BLU-554 Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Key Confirmed diagnosis HCC histological examination noninvasive criterion accord European Association Study Liver ( EASL ) American Association Study Liver Disease ( AASLD ) guideline . Patient unresectable disease previously treat sorafenib , decline treatment sorafenib , access sorafenib . OR In Part 1 , confirm diagnosis relapse refractory advance solid tumor HCC evidence aberrant FGF19/FGFR4 pathway activity [ e.g . tumor blood/plasma alteration include , limited , 11q13.1 locus ( FGF19/CCND1 ( cyclin D1 ) ) amplification/copy number gain ] ChildPugh class A clinically apparent ascites Eastern Cooperative Oncology Group ( ECOG ) performance status 01 For Part 1 , willing provide archive tumor tissue ( available ) willing undergo pre ontreatment tumor biopsy ( consider safe medically feasible treat investigator ) For Part 2 , patient must FGF19 IHC result available . Only FGF19 IHC positive HCC patient eligible Part 2 bid dose schedule . Key Central nervous system metastases Platelet count &lt; 75,000/mL Absolute neutrophil count &lt; 1000/mL Hemoglobin &lt; 8 g/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 5x upper limit normal ( ULN ) Total bilirubin &gt; 2.5 mg/dL International normalized ratio ( INR ) &gt; 2.3 prothrombin time ( PT ) &gt; 6 second control Estimated ( CockroftGault formula ) measure creatinine clearance &lt; 40 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Liver cancer</keyword>
	<keyword>FGF19 gene amplification</keyword>
	<keyword>FGF19 overexpression</keyword>
	<keyword>FGF19 upregulation</keyword>
	<keyword>Cyclin D1 ( CCND1 ) gene amplification</keyword>
	<keyword>Cyclin D1 ( CCND1 ) copy number gain</keyword>
	<keyword>BLU-554</keyword>
	<keyword>FGFR4</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Liver Neoplasms</keyword>
</DOC>